EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease Presented ByProf. Marc Ferrante, KU Leuven, Belgium TrialEVOLVE ConferenceDDW 2023 13 June, 2023 13:56
Vedolizumab and anti-TNF therapies: a real-world comparison Presented ByDr G. Mantzaris , Evangelismos Hospital, Greece TrialEVOLVE ConferenceECCO 2020 14 April, 2020 15:35